News
Sarepta Therapeutics (SRPT) stock in focus as report says company hired a Trump-linked lobbying firm after deaths linked to ...
A 26-year-old Downriver man seen at Children’s Hospital of Michigan in Detroit since infancy for a rare bleeding disorder in ...
After a second Elevidys patient death from acute liver failure, Sarepta in July launched a major restructuring that involves ...
Connecticut is now participating in a new federal program aimed at expanding treatment access for patients with sickle cell ...
Enrollment Complete in Cohorts 1 and 2 of MyPEAK™-1 Phase 1b/2 Trial of TN-201 for MYBPC3-associated HCM; Positive DSMB ...
Cash runway extended into 2028; expected to enable multiple meaningful clinical data read-outs -- APOE program added to ...
At only 6 months, Gerard and Kaitlin Norton’s daughter Madeline was diagnosed with PKAN, a rare neurodegenerative disorder ...
Sarepta Therapeutics hired a Trump-connected lobbying firm after the death of a teenage boy treated with its Duchenne ...
7h
GlobalData on MSNNovo Nordisk to advance ATTR amyloidosis mAb to Phase III
Novo Nordisk will advance its acquired ATTR amyloidosis with cardiomyopathy monoclonal antibody (mAb) to Phase III trials.
Excellos brings its donor-to-dose capabilities—including donor management, apheresis, cell characterization, and GMP ...
In this week’s edition of InnovationRx, we look at a biotech entrepreneur treating a rare genetic disease, new tech aimed at ...
LEXINGTON, Mass. (AP) — LEXINGTON, Mass. (AP) — Voyager Therapeutics Inc. (VYGR) on Wednesday reported a loss of $33.4 million in its second quarter. On a per-share basis, the Lexington, Massachusetts ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results